Savara Inc. SVRA R2K

Healthcare · Biotechnology · United States

https://www.savarapharma.com

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Market & Price

Market Cap

$1.07B

Current Price

$5.20

High / Low (52W)

$6.94 / $2.04

Beta

0.28

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$0.80

Price to Book

6.48

P/S

EV/EBITDA

-8.59

Dividend Yield

Profitability & Returns

ROCE

-52.68%

ROE

-79.95%

ROA

-40.53%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.15

EPS (TTM)

$-0.56

Balance Sheet & Liquidity

Debt/Equity

0.17

Quick Ratio

13.21

Current Ratio

13.47

Debt

$30.11M

Total Assets

$253.44M

Current Assets

$241.62M

Working Capital

$221.22M

Ownership

Promoter Holding

2.62%

Chg in Prom Hold

FII / Inst Holding

104.25%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.14B

Total Revenue (TTM)

EBITDA

$-133.17M

Free Cash Flow

$-57.65M

Operating Cash Flow

$-106.89M

Shares Outstanding

204.93M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-70.50%

Revenue (YoY)

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -70.5% CAGR over 5 years.
Trading 25.1% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SVRA Savara Inc. R2K	5.20	-	$1.07B	-	-52.68%	-79.95%	-	-70.50%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	256.00K	-	-	0	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27.65M	31.44M	30.25M	33.42M	38.14M
Operating Income	-9.65M	-10.18M	-9.83M	-9.71M	-1.69M	-1.98M	-3.23M	-4.04M	-4.77M	-9.34M	-6.54M	-9.30M	-32.11M	-11.91M	-12.78M	-13.25M	-12.92M	-22.15M	-12.44M	-31.51M	-16.24M	-9.26M	-10.79M	-10.41M	-10.45M	-9.97M	-8.05M	-9.38M	-10.54M	-12.11M	-12.22M	-18.04M	-22.48M	-23.19M	-	-27.65M	-31.44M	-30.25M	-33.42M	-38.14M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-27.58M	-31.37M	-30.18M	-33.43M	-38.07M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-26.64M	-30.40M	-29.56M	-32.24M	-37.28M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Net Income	-9.62M	-10.15M	-9.91M	-10.16M	-1.68M	-2.05M	-3.23M	-3.97M	-4.97M	-11.50M	-6.82M	-6.50M	-26.85M	-11.59M	-12.56M	-10.51M	-12.11M	-21.94M	-12.40M	-31.72M	-15.42M	-9.39M	-11.06M	-10.22M	-10.94M	-10.55M	-8.30M	-9.16M	-10.39M	-10.56M	-11.44M	-16.60M	-20.35M	-22.24M	-	-26.64M	-30.40M	-29.56M	-32.24M	-37.28M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.07	-0.07	-0.05	-0.06	-0.07	-0.07	-0.07	-0.10	-0.11	-0.12	-0.11	-0.12	-0.14	-0.14	-	-0.15
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.40M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	257.00K	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	488.96K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38.04M	59.21M	102.40M	122.76M
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-8.54M	-13.40M	-15.63M	-21.54M	-29.28M	-5.92M	-10.95M	-29.96M	-70.05M	-79.03M	-49.30M	-	-38.04M	-59.21M	-102.40M	-122.76M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-37.88M	-59.13M	-102.27M	-122.68M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.28M	88.00K	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-38.15M	-54.70M	-95.88M	-118.84M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-1.98M	-1.20M	-1.06M	-3.70M	-16.34M	-2.11M	-2.33M	-6.70M	-24.78M	-29.33M	-22.14M	-26.65M	-11.33M	-8.45M	-13.26M	-15.56M	-21.48M	-28.70M	-9.00M	-10.92M	-29.80M	-61.52M	-78.17M	-49.62M	-	-38.15M	-54.70M	-95.88M	-118.84M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.25	-0.33	-0.48	-0.53

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	-70.50%
1 Year:	-

Stock Price Performance

1 Year:	+128.07%
6 Months:	+0.97%
3 Months:	-13.62%
1 Month:	+7.22%

Balance Sheet (Annual)

Figures in USD.

Metric	Jun 1996	Dec 1996	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28.49M	61.86M	46.97M	55.25M	70.50M	54.22M	28.93M	159.63M	152.29M	136.20M	97.75M	-	139.78M	177.56M	212.88M	253.44M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	128.95M	165.95M	202.13M	241.62M
Cash & Equivalents	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.67M	27.98M	43.57M	22.50M	25.68M	12.69M	16.68M	13.37M	22.12M	24.30M	49.80M	22.88M	-	52.10M	26.59M	15.13M	33.18M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	954.00K	1.00M	1.04M	1.25M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.80M	5.08M	5.18M	7.44M	11.84M	30.33M	20.95M	40.32M	44.07M	34.51M	33.36M	-	32.00M	37.19M	41.43M	50.30M
Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.80M	2.47M	2.57M	4.83M	8.44M	23.17M	3.46M	6.01M	7.25M	10.88M	8.17M	-	5.87M	10.60M	14.72M	20.40M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.10M	-	26.08M	26.35M	26.62M	29.91M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26.14M	26.49M	26.73M	29.91M
Total Equity	0	-272.62K	382.21K	-525.26K	-1.23M	14.61M	-638.49K	-852.73K	4.12M	12.39M	-7.83M	19.96M	31.03M	6.00M	6.67M	26.69M	56.78M	41.79M	47.81M	-18.30M	-27.33M	-35.88M	119.31M	108.22M	101.70M	64.38M	-	107.78M	140.37M	171.45M	203.13M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	114.05M	138.14M	172.42M	204.57M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-8.34M	-13.47M	-13.92M	-17.79M	-	-	-	-28.23M	-39.27M	-45.12M	-39.84M	-	-34.55M	-51.06M	-89.09M	-101.04M
Investing Cash Flow	-24.13K	-7.54M	-7.17M	-4.77M	-	-	-	-69.11M	-13.62M	15.74M	9.05M	-	52.65M	-57.12M	-39.94M	-18.44M
Financing Cash Flow	27.68M	36.60M	740	25.74M	-	-	-	106.09M	55.19M	54.91M	3.69M	-	87.00K	82.78M	117.58M	137.81M
Capital Expenditure	-28.51K	-411.76K	-266.18K	-47.00K	-147.00K	-165.00K	-8.00K	-495.00K	-141.00K	-148.00K	-47.00K	-	-9.00K	-296.00K	-25.00K	-22.00K
Free Cash Flow	-8.37M	-13.88M	-14.19M	-17.84M	-	-	-	-28.73M	-39.42M	-45.27M	-39.88M	-	-34.56M	-51.36M	-89.11M	-101.06M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	18.18M	-25.40M	-11.45M	18.33M

Ratios (Annual)

Figures in %.

Metric	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-19,182.9%	-	-	-	-	-
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-19,305.4%	-	-	-	-	-
ROE %	-517.9%	229.3%	85.6%	-25.3%	2,559.0%	246.9%	-56.6%	-54.1%	316.6%	-147.0%	-71.3%	-444.5%	-169.7%	-31.7%	-23.4%	-37.2%	-44.9%	156.9%	32.9%	30.4%	-25.0%	-56.8%	-76.9%	-77.1%	-	-35.4%	-39.0%	-55.9%	-58.5%
ROCE %	-	-	-	-	-	-	-	-	-	-	-	-	-	-32.0%	-22.6%	-35.2%	-42.7%	-47.2%	-19.1%	-43.0%	-19.5%	-48.3%	-63.1%	-55.0%	-	-28.4%	-35.5%	-51.7%	-52.7%

Shareholding Pattern

Insiders

2.62%

Institutions

104.25%

Public Float

107.06%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	NEA Management Company, LLC	11.94%	24.47M	$127.25M
2	Bain Capital Life Sciences Investors, LLC	8.59%	17.60M	$91.52M
3	Venrock Adviser, LLC	6.71%	13.74M	$71.45M
4	Deerfield Management Company, L.P	6.62%	13.57M	$70.56M
5	TCG Crossover Management, LLC	6.03%	12.36M	$64.28M
6	Blackrock Inc.	5.51%	11.29M	$58.71M
7	Frazier Life Sciences Management, L.P.	4.74%	9.72M	$50.55M
8	Polar Capital Holdings PLC	4.66%	9.54M	$49.62M
9	Vanguard Capital Management LLC	3.80%	7.78M	$40.48M
10	Nantahala Capital Management, LLC	3.58%	7.34M	$38.19M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SVRA

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Sector	Healthcare
Industry	Biotechnology
Headquarters	United States
Employees	70
Website	https://www.savarapharma.com

Savara Inc. SVRA R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More